Literature DB >> 33828233

Engaging results with glofitamab.

David Killock1.   

Abstract

Entities:  

Year:  2021        PMID： 33828233     DOI： 10.1038/s41571-021-00510-3

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

Authors:  Martin Hutchings; Franck Morschhauser; Gloria Iacoboni; Carmelo Carlo-Stella; Fritz C Offner; Anna Sureda; Gilles Salles; Joaquín Martínez-Lopez; Michael Crump; Denise N Thomas; Peter N Morcos; Cristiano Ferlini; Ann-Marie E Bröske; Anton Belousov; Marina Bacac; Natalie Dimier; David J Carlile; Linda Lundberg; David Perez-Callejo; Pablo Umaña; Tom Moore; Martin Weisser; Michael J Dickinson
Journal:  J Clin Oncol       Date:  2021-03-19       Impact factor: 50.717
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.